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Abstract 
Human neurodegenerative diseases have no disease-modifying treatments. We used 
spinocerebellar ataxia type 2 (SCA2), an autosomal dominant polyglutamine disease, as a 
model to test RNA-targeted therapies in two SCA2 mouse models. Both models recreate 
progressive adult-onset dysfunction and degeneration of a neuronal network including 
decreased firing frequency of cerebellar Purkinje cells (PCs) and decline in motor function. 
We developed a potential therapy directed at the ATXN2 gene by screening 152 antisense 
oligonucleotides (ASOs). Here we show that the most promising lead ASO7 downregulated 
ATXN2 mRNA and protein resulting in delayed onset of SCA2 phenotypes. After delivery 
by intracerebroventricular injection (ICV) to ATXN2-Q127 mice, ASO7 localized to PCs, 
reduced cerebellar ATXN2 expression below 75% for >10 weeks without microglial 
activation, and reduced cerebellar ataxin-2 protein. ASO7 treatment of symptomatic mice 
improved motor functioning compared to saline-treated mice. ASO7 had a similar effect in 
the BAC-Q72 SCA2 mouse model, and in both mouse models it normalized protein levels 
of several key PC proteins including Pcp2 and Rgs8. Most surprisingly, firing frequency of 
PCs returned to normal even when treatment was initiated 12 weeks after motor phenotype 
onset in BAC-Q72 mice. These findings support ASOs as a promising approach for 
treating some human neurodegenerative diseases. 
SCA2 is caused by DNA CAG repeat expansion leading to an increase in the polyglutamine 
(polyQ) domain in the N-terminal part of the ATXN2 protein. Although the disease was initially 
described as a cerebellar degeneration, it is now known to involve multiple neuronal groups 
outside the cerebellum. SCA2 may even present as amyotrophic lateral sclerosis (ALS) or 
Parkinson disease1,2. Given the different physiology of affected neurons and their wide CNS 
distribution, therapeutics that directly engage their target with high specificity and CNS 
distribution are needed. Neurodegenerative diseases caused by dominant mutations in human 
genes have been difficult to approach therapeutically, and few studies have targeted disease 
genes directly as the first step in pathogenesis (discussed below). Although targeting the 
mutation itself appears attractive, this approach has proven to be technically difficult in polyQ 
diseases. We have used spinocerebellar ataxia type 2, a human neurodegenerative disease, as 
a model to develop an approach to use ASOs to directly target the ATXN2 mRNA. 
ASOs have undergone significant development since their first use3. Modification of DNA 
backbone chemistry has reduced toxicity, increased target engagement and destruction of DNA-
RNA hybrids. designed multiple chimeric 2’-O-methoxyethyl (MOE)/DNA gapmer ASOs 
targeting ATXN2 for an in vitro screen and screened for ATXN2 RNA reduction in a cell based 
assay, identifying several ASOs that reduced ATXN2 expression. After testing of ASOs for in 
vivo tolerability, we tested one ASO in detailed behavioral, biochemical and physiologic studies. 
This ASO targets exon 11 of human ATXN2 and is designated ASO7. 
Prior studies indicated that dosage of the polyQ expanded ATXN2 is important in pathology as 
homozygote animals developed more severe disease manifestations4. On the other hand, 
reducing ATXN2 dosage did not affect fertility, survival or CNS morphology in heterozygous or 
homozygous knock-out animals5. These observations suggested that reducing ATXN2 
expression using ASOs would present a viable strategy for SCA2-mediated neurodegeneration.  
Our in vitro screen included 152 ASOs designed in silico for targeting human ATXN2. The top 8 
lead ASOs lowered ATXN2 expression by ≥85% (Extended Data Fig. 1, Supplementary Table 
1). In vivo testing revealed ASO7 and two other ASOs among the most effective for lowering 
ATXN2 expression after 7 d treatment (Extended Data Fig. 2a-c). To confirm that the ASOs 
were well tolerated, we monitored for glial and microglial activation by measuring Gfap and Aif1 
expression in cerebella by qPCR. Some ASOs were not further pursued owing to activation of 
glial or microglial responses in > 10 wk treatments. We did not observe gliosis activation for 
ASO7 (Extended Data Fig. 2a-c, and 3). We verified that ASO7 as well as other lead ASOs 
were taken up by PCs by IHC (Extended Data Fig. 2d, e-i).  
ATXN2-Q127 mice have a human ATXN2 cDNA transgene with 127 CAG repeats. We treated 
ATXN2-Q127 mice ICV at 8 wks of age, coinciding with the age of motor phenotype onset6, with 
ASO7 and tested motor performance on the accelerating rotarod at weeks 5, 9, and 13 after ICV 
injection.  Consensus criteria for the conduct of preclinical trials were closely followed (see 
Supplementary Discussion). Progression of motor dysfunction in saline treated mice was 
significant and as previously observed6. Mice injected with ASO7 had significantly improved 
motor performance compared to saline-treated control mice (Fig. 1a), and human and mouse 
Atxn2 mRNA expression was reduced by 75% and 20%, respectively, after motor phenotype 
testing demonstrating target engagement (Fig. 2a-c).  
In preclinical studies, it is important to test compounds in multiple models of the human disease. 
We therefore developed a mouse model that replicated the human disease more closely by 
expressing a bacterial-artificial-chromosome (BAC) transgene incorporating the human 
promoter as well as all exons and introns and flanking regions. The BAC resulted in expression 
of ATXN2 with 72 glutamines in multiple neuronal tissues including spinal cord7. The BAC-Q72 
model approximates human disease not only with regard to disease manifestations and less 
dramatic progression, but also because it contains the entire human gene in its proper intronic-
exonic context. We conducted an additional preclinical trial in this mouse model with treatment 
initiated at 30 wks of age, 12 wks after motor phenotype onset. Again, the mutated human 
ATXN2 and mouse Atxn2 were engaged by ASO7 with mRNA levels reduced by 60% and 26%, 
respectively (Fig. 2d), and human ATXN2 was not detected in cerebellar lysates from treated 
mice by Western blotting (Fig. 2e, f). When tested 10 weeks after ICV injection, significant 
improvement in motor behavior compared to saline-ICV injected mice was seen (Fig. 1b). 
However, the rotarod performance of the ASO7 treated mice did not perfectly mirror that of 
wildtype mice. This might indicate that additional treatment time would be necessary to more 
completely restore cerebellar function. Body weights taken after rotarod testing indicated that 
the rotarod results observed were not impacted by different mouse weights between the 
experimental groups (Extended Data Fig. 4). 
Previously, we established transcriptome and protein profiles characterized by progressive 
changes in the course of degeneration in both mouse models7. To evaluate the effect of ASO7 
on steady-state mRNA and protein levels we chose the top 6 mRNAs that showed the most 
significant changes in an age-dependent manner and were shared in both mouse models.7  
Given that the Pcp2-Q127 model expresses the transgene specifically in PCs, the six genes are 
all highly and specifically expressed in PCs. These include Rgs8, Pcp2, Pcp4, Cep76, Homer3 
and Fam107b7. RGS proteins inhibit mGlur18, which is a positive regulator of Ca2+ release from 
internal stores9_ENREF_10. Because mGlur1 signaling is disrupted in SCA2 PCs leading to 
abnormal Ca2+ release, mGlur1 regulation may also be a function of Rgs87,10. mGlur1 is also 
regulated in PCs by Homer311. Pcp2 is a regulator of G(i/o)-coupled receptors including the P-
type Ca2+ channel, important for sensorimotor control12. Pcp4 loss causes abnormal PC parallel 
fiber synapses13, and Cep76 is required for normal centriole function14. Little is known of 
Fam107b function, however. Fam107b and Rgs8 were identified as cerebellar hub genes with 
reduced expression in SCA1 mice15. Although changes at the mRNA level were minor, we 
observed restored expression at the protein level for all six of the genes on Western blots (Fig. 
2, with full length Western blots provided in Extended Data Fig. 5). This observation is 
consistent with an emerging role of polyglutamine expanded ATXN2 in translational 
dysregulation7,16.  
PCs are spontaneously firing neurons with a resting firing frequency of 40-50 Hz in mammals. 
The cerebellar circuits underlying cerebellar learning and functioning are well understood10,17,18 
with PCs integrating signals received from parallel and climbing fibers and providing the only 
output from the cerebellar cortex to the deep cerebellar nuclei (DCN). In acute slice 
preparations, we had previously shown that mutant ATXN2 caused a slowing of PC firing. This 
change had an onset and progression that closely mirrored that of motor deficits with onset at 6-
8 weeks and an eventual slowing to 20 Hz at 24 weeks of age6. It has been suggested that the 
change in PC physiology is tightly linked to Ca2+ homeostasis and subsequent cell death10,19. 
This tight linkage between behavior and physiology led us to hypothesize that ASO treatment 
would restore normal PC firing. We injected ATXN2-Q127 mice at 8 wks and analyzed PC 
physiology 6 and 14 wks later in acute cerebellar slices. Similarly, we injected BAC-Q72 mice at 
30 wks and analyzed PC firing 10 wks later. In both models, a single injection of ASO7 resulted 
in near complete restoration of normal PC firing frequency (Figs 3-4). These results suggest that 
ATXN2 ASO treatment directly affects PC physiology and at least in part explains the 
amelioration of motor behavior.  
SCA2 and other polyglutamine diseases are characterized by toxic gains of function, suggesting 
that therapeutics that lower expression of the disease causing genes would be beneficial. ASOs 
represent an ideal approach for directly lowering ATXN2 expression because ASOs are 
sequence specific, well tolerated, can reach CNS targets by intrathecal delivery, and are 
currently in early-phase  human clinical trials, including the neurodegenerative disorders SMA 
and SOD1-ALS20,21. Various approaches to ASO therapeutics for polyglutamine diseases have 
been developed including targeting wildtype and mutant alleles as in this study or attempting to 
target mutant alleles via the expanded CAG repeat or via SNPs in linkage disequilibrium with 
the mutation22,23. DCN injected adeno-associated viruses (AAVs) targeting shRNAs to PCs were 
also effective for SCA1, reducing target expression and improving motor and cerebellar 
phenotypes in SCA1 transgenic mice24,25. At least for SCA2 and with the caveats of preclinical 
mouse studies, the strategy of targeting both mutant and WT alleles is showing promise. One 
potential advantage of ASOs over current viral vectors is the ability of ASO to distribute through 
the nervous system whereas adenoviral vectors are only transported transynaptically. Thus for 
SCA2, AAVs injected into DCN neurons would reach PCs, but may not reach other neuronal 
groups. 
In conclusion, we rigorously screened ASOs to identify a potent and well tolerated ASO, ASO7, 
that lowered cerebellar ATXN2 expression, and verified in two SCA2 models that ASO7 delayed 
SCA2 motor and electrophysiological phenotypes in replicate experiments. Cerebellar 
degenerative diseases provide excellent model systems to study the interaction of dysfunction 
in a neuronal network, behavior and neurodegeneration. Our studies suggest that reduction of 
mutant ATXN2 effects all three domains including endophenotypic markers of cell death 
common in ataxias7,15,26_ENREF_10. Multiple lines of evidence suggest that ASOs may have 
application in human patients. ASO7 lowered expression of wildtype and mutant ATXN2 in 
SCA2 patient-derived fibroblasts (Extended Data Fig. 6). ASO7 delivered by ICV injection 
localized throughout the spinal column and lowered ATXN2 expression not only in brain, but 
also in spinal cord (data not shown). Notably, unpublished studies in ALS models suggest that 
lowering of ATXN2 by ASO treatment or genetic interaction may greatly delay dysfunction and 
death in mice (Aaron Gitler, Personal communication). ASO7 or ASOs with further modifications 
in ASO chemistry may provide an effective human drug for SCA2, ALS caused by ATXN2 
mutation and other forms of ALS. 
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Figure Legends 
Figure 1  Effect of ASO7 on motor phenotypes. a, Eight wk old ATXN2-Q127 mice were treated 
with 210 μg ASO7 or saline ICV and rotorod tested at the indicated ages. n=15 mice per group. 
b, Eight wk old BAC-Q72 mice and wildtype littermates were treated with 175 μg ASO7 or saline 
ICV and rotarod tested at the indicated ages. n= 13, 13, 11, 14 for WT-ASO, WT-Saline, TG-
ASO, and TG-Saline, respectively. Values shown are mean±SE. Probabilities of significance 
were determined using the method of generalized estimating equations (GEE). NS, 
nonsignificant, *=p<0.05, **=p<0.01. 
Figure 2 Cerebellar gene expression for ASO treated SCA2 mice following rotatod tests.  a-c, 
Expression in ATXN2-Q127 mice. a, ATXN2-Q127 mice were treated as in Fig. 1a and the 
cerebellar expression of the indicated genes was determined at 22 wks of age. The n number of 
mice for saline and ASO7 treatments, respectively, were:  ATXN2, 11, 11; Atxn2, 11, 11; Aif1, 7, 
8; Gfap, 11, 11; Rgs8, 4, 4; Pcp2, 11, 11; Pcp4, 10, 11; Cep76, 10, 11; Homer3, 10, 11; 
Fam107b, 10, 10. b & c, Cerebellar expression in ATXN2-Q127 mice for ATXN2, mouse Atxn2, 
Rgs8, Pcp2, Pcp4, Cep76, Homer3, Fam107b, and Actin (b), with abundances expressed as a 
percent relative to actin, determined densitometrically (c).  d-f, Expression in BAC-Q72 mice. d, 
BAC-Q72 mice were treated as in Fig. 1b and the cerebellar expression of the indicated genes 
was determined at 19 wks of age. The n per group in qPCR analyses was 14 saline treated 
mice and 11 ASO7 treated mice for all genes except Rgs8 and Fam107b where the n was 14 
saline treated and 10 ASO treated mice. Values are mean±SD. NS, nonsignificant, *=p<0.05, 
**=p<0.01, ***=p<0.001 by Student’s t-test. e, Cerebellar expression in BAC-Q72 mice of 
expanded ATXN2 detected with anti-1C2 antibody, and expression of mouse Atxn2, Rgs8, 
Pcp2, Pcp4, Cep76, Homer3, Fam107b and Actin (e), with abundances expressed as a percent 
relative to actin, determined densitometrically (f). Values shown in c and f are mean±SD from 
three replicate blots.  
Figure 3  Slow ATXN2-Q127 mouse PC firing frequency (FF) was restored by ASO7. a-d, 
ATXN2-Q127 mice were treated with 210 μg ASO7 or saline by ICV injection at 8 wks, and PC 
FF was evaluated at 14 wks of age. a, Mean FF distribution for PCs from saline and ASO7 
treated mice. b, Representative PC traces of 1s duration, and (c) interspike-interval histogram 
of the same cell as in (b) calculated from 2 min duration, with coefficients of variation (CV) 
shown. d, Mean FF (±SEM) were 25±2 Hz for the saline treated mouse (n=50 neurons, mice=1) 
and 46±2 Hz for the ASO7 treated mice (n=88 neurons, mice=2) (****, p<0.0001, Student’s t-
test). e-h, ATXN2-Q127 mice were treated with 210 μg ASO7 or saline by ICV injection at 8 
wks. PC FF was evaluated at 22 weeks of age. e, Mean FFs of all PCs measured from saline 
and ASO7 treated mice and age-matched WT mice. f, Representative PC  traces of 1s duration, 
and (g) interspike-interval histogram of the same cell as in (f) calculated from 2 min duration, 
with CV values shown. h, Mean FF (± SEM)  were 16±1 Hz for the saline treated ATXN2-Q127 
mice (n=107 neurons, mice=2), 42±2 Hz for the ASO7 treated ATXN2-Q127 mice (n=102 
neurons, mice=2), and 40±1 Hz for an age-matched WT mouse (n=50 neurons, mice=1). (****, 
p<0.0001, Student’s t-test). 
Figure 4   Slow BAC-Q72 mouse PC FF was restored by ASO7. a-c, FFs of BAC-Q72 mice at 
indicated ages. a, FF distributions for WT and BAC-Q72 PCs. The n number of PCs were 33 
WT, 59 BAC-Q72 (4 mo); 49 WT, 101 BAC-Q72 (6 mo); 55 WT, 92 BAC-Q72 (12 mo). b, 
Example recordings from PCs for WT and BAC-Q72 mice. c, Interspike intervals of the same 
cell over 2 min with mean FF and CV indicated. d-f, The PC FF was restored in 10 mo. old 
BAC-Q72 mice treated with 210 μg ASO7 ICV for 10 wks. d, PC FF in BAC-Q72 mice, BAC-
Q72 mice treated with ASO7, and WT littermates. e, Representative PC 1s trace and (f) 
interspike intervals of the same cell over 2 min in saline treated BAC-Q72 mice, ASO treated 
BAC-Q72, and WT littermates with PC FF and CV indicated. g-h, Mean PC FFs in (a) and (d).  
g, Age-dependent PC FF in BAC-Q72 mice. At age 4 mo the mean FFs in Hz were 51±2 for WT 
(n=33 PCs, mice=1) and 54±2 for BAC-Q72 (n= 59 PCs, mice=1). At 6 mo the values were 
41±2 for WT (n=49 PCs, mice=2) and 32±1 for BAC-Q72 (n=101 PCs, mice=2). At age 12 mo 
they were 49±2 for WT (n=55 PCs, mice=1) and 34±1 for BAC-Q72 (n=92 PCs, n=1). h, ASO7 
treatment restored the PC FF of BAC-Q72 mice. The mean PC FF for 10 mo old BAC-Q72 mice 
treated with saline was 36±1 Hz (n=148 PCs, mice=3) while the mean FF of BAC-Q72 mice 
treated with ASO7 was 49±1 (n=134 PCs, mice=4), similar to that of WT mice (49±1, n=155 
PCs, mice=3). (****, p<0.0001, ANOVA followed by Tukey’s multiple comparison posthoc 
testing). 
  
Extended Data Figure Legends 
Extended Data Figure 1  In vitro screen for ATXN2 ASOs by qPCR. A total of 152 ASOs were 
delivered at 4.5 μM to HepG2 cells by electroporation in two 384-well plates. ATXN2 expression 
was evaluated by qPCR (n=3 wells per ASO). Shown is the evaluation of the eight best positive 
hit ASOs for IC50 determination. Values are means ± SD of ATXN2 quantity relative to total 
RNA. Cont. = scrambled control ASO. 
Extended Data Figure 2  Positive hit ASOs evaluated in vivo. a-c, 250 μg of the indicated 
ASOs in a total of 7 μl was delivered by ICV injection. After 7 days treatment the expression of 
mouse Atxn2 or human ATXN2 and Aif1 was determined by qPCR relative to actin. a, Wildtype 
FVB mice. b, BAC-Q72 mice. c, ATXN2-Q127 mice. Values are means ± SD relative to those 
determined from normal saline treated mice. The n number of mice (left-to-right in each chart) 
was as follows: a, 2,2,2,3,2,2,2,2,1. b, 2,1,1,2,2,2,1,2. c, 2,3,1,1,1. d & e, ASOs localized to the 
cerebellar Purkinje cell layer of treated mice. Mice were treated by ICV injection into the right 
lateral ventricle of the indicated lead ASOs for 7 days in BAC-Q72 mice (ASO3 and ASO7 used 
at 250 μg) or 10 wks in ATXN2-Q127 mice (ASO1 used at 200 μg). ASOs were localized in 
paraffin embedded sections by immunohistochemical peroxidase staining using anti-ASO 
antibody. Saline= ATXN2-Q127 mice treated by ICV injection of 7 μl saline for 10 wks. d, 10x 
objective. e, 3x digital zoom of a region of the PC layer in the corresponding 10x image, 
indicated by the box. Bar = 100 μm (d), 25 μm (e). f-i, Distribution of ASO7 in the cerebellum. f, 
ASO7 was distributed in Purkinje cell layers throughout the cerebellum (2x objective). Higher 
power images at regions indicated in f demonstrated ASO7 localization in Purkinje cells across 
the cerebellum: g, 10x objective; h & i, 40x objective.  
Extended Data Figure 3  Effects of ASO7 on ATXN2 expression in vivo by dose and time. a-c,  
Dosewise effect of ASO7 on ATXN2 expression in BAC-Q72 mice treated with ASO7 by ICV 
injection for 14 days. a, Expression of cerebellar human ATXN2 and mouse Atxn2 determined 
by qPCR.  b, Cerebellar Aif1 expression determined by qPCR. c, Cerebellar Gfap expression 
determined by qPCR.  The N # of mice for the saline, 52 μg, 105 μg, and 210 μg treatments was 
3, 2, 3 and 3, respectively. 
Extended Data Figure 4  Weights of mice before and after rotarod testing.  a, Rotarod test of 
ATXN2-Q127 mice treated with a single ICV dose of 210 μg ASO7. b, Rotarod test of BAC-Q72 
mice treated with a single ICV dose of 175 μg ASO7. Weeks of ASO treatments are indicated 
on the X-axes. Significance tests demonstrated significant differences between weights of BAC-
Q72 mice compared to wildtype littermates (p<0.001 for any age group, Student’s t-test). 
Comments on the relevance of mouse weights on motor phenotype testing are provided in 
Supplementary Discussion. 
Extended Data Figure 5  Full length Western blots corresponding to Figs. 2b and 2e. 
Extended Data Figure 6  ASO7 lowered expression of wildtype and mutant ATXN2 in cultured 
SCA2 patient derived fibroblasts. a, Patient derived SCA2(CAG35) fibroblasts were transfected 
with the indicated quantities of ASO7. After 72 hours RNAs were prepared and total ATXN2 
expression was determined by qPCR.  b, To determine ASO7 effect on the expression of non-
mutant (CAG22) and mutant (CAG35) ATXN2, RT-PCR reactions were evaluated by agarose 
gel electrophoresis, with loading controlled by GAPDH. 
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METHODS 
SCA2 mice 
Pcp2-ATXN2-Q127 (ATXN2-Q127) transgenic mice express the full-length human ATXN2-
[CAG]127 cDNA under the control of the mouse Purkinje cell protein 2 (L7) promoter (Pcp2). 
ATXN2-Q127 mice in this study had a B6;D2 hybrid background. ATXN2-Q127 mice are 
described in Hansen et al., 2013 and Dansithong et al., 20151,2. BAC-ATXN2-Q72 (BAC-Q72) 
mice were created using a contiguous 169 kb human ATXN2 gene sequence including 16 kb 
upstream ATXN2 sequence, the entire ATXN2-[CAG]72 coding region (with introns) and 3 kb of 
ATXN2 3’-UTR and downstream sequence. BAC-Q22 are identical to BAC-Q72 but with the 
normal length CAG repeat. BAC-Q72 and BAC-Q72 mice used in this study had a FVB;B6 
hybrid background. Creation of BAC-Q72 and BAC-Q22 mice is described in Dansithong et al., 
20151. BAC-Q22 mice were used in some in vivo ASO testing experiments that are not shown. 
Animals were genotyped by two separate PCR reactions using SCA2A/SCA2B and BM13-
F/BM14-R genotyping primers (Supplementary Table 2). All animal work was done under an 
approved IACUC protocols at the University of Utah and University of California Los Angeles. 
One week post-surgery animals were recombined into cages of four mice for the duration of the 
study. To ensure blinding, ASO treated and saline treated mice were housed together and the 
technician performing behavioral testing was not aware of treatment status. Comments on study 
rigor including blinding are provided in Supplemental Discussion. 
Antisense Oligonucleotides 
All antisense oligonucleotides were 20 bp in length, included five 2’-O-methoxyethyl (MOE) 
modified nucleotides at each end of the oligonucleotide, with ten DNA nucleotides in the center, 
and were phosphorothioate modified in all positions. ASOs were synthesized as previously 
described3. The program Bowtie4 was used to determine the predicted off-targets for the ATXN2 
ASOs in the mouse transcriptome (pre- and m-RNA). This analysis confirmed that the ATXN2 
ASOs do not bind any RNA other than ATXN2 with full complementarity. We further verified that 
none of the lead ASOs had sequences that would target the closely homologous ATXN2L gene.    
ICV ASO Injections 
ASOs were delivered to mice by intracerebroventricular (ICV) injection. Injection were made 
using a Hamilton 26s gauge needle. For mice in Figs 1-4 injections were 6 µl of 35 µg/µl ASO7 
diluted in normal saline for a total of 210 µg. Control mice received the same volume of normal 
saline. For other mice in Extended Data Figures injection volumes varied from 6-10 µl to deliver 
the indicated ASO concentrations, with ASOs diluted accordingly with normal saline. Injections 
were made under anesthesia with a mixture of oxygen and isoflurane, using a Stoelting 
stereotaxic frame. Anesthesia was initiated using 3% isoflurane for 5 min and the isoflurane 
mixture was lowered to 2% during injections. Stereotaxic bregma coordinates were -0.46 mm 
anteroposterior, -1.0 mm lateral (right side); -2.5 mm dorsoventral. Needles were removed 4 min 
after ASO delivery. Mice were maintained on a 39°C isothermal pad while anesthesized and 
during recovery.  
Cell culture 
SCA2 patient-derived skin fibroblasts (SCA2-CAG35) were cultured and maintained in DMEM 
medium supplemented with 10% fetal bovine serum, penicillin and streptomycin. All subjects 
gave written consent and the studies were approved by the Institutional Review Board at the 
University of Utah.  ASO transfections were performed by electroporation of,one million cells 
with 0, 0.35, 1 or 2 μM ASO7 using the Neon transfection system (Invitrogen Inc., USA) 
according to manufacturer’s protocol, followed by plating in 6 well plates.. The cells were 
harvested at 5 days post-electroporation for analyses.  
Western blot analyses 
Protein extracts were prepared by homogenization of mouse cerebella in extraction buffer (25 
mM Tris-HCl pH 7.6, 300 mM NaCl, 0.5% Nonidet P-40, 2 mM EDTA, 2 mM MgCl2, 0.5 M urea 
and protease inhibitors; Sigma; cat# P-8340) followed by centrifugation at 4°C for 20 min at 
16,100 × g. Only supernatants were used for Western blotting to determine the steady-state 
levels of proteins using the antibodies listed below. Protein extracts were resolved by SDS-
PAGE and transferred to Hybond P membranes (Amersham Bioscience Inc., USA). After 
blocking with 5% skim milk in 0.1% Tween 20/PBS, the membranes were incubated with 
primary antibodies in 5% skim milk in 0.1% Tween 20/PBS for 2 hrs at room temperature or 
overnight at 4°C. After washing in 0.1% Tween 20/PBS, the membranes were incubated with 
the corresponding secondary antibodies conjugated with HRP in 5% skim milk in 0.1% Tween 
20/PBS for 2 hrs at room temperature and washed again. Signals were detected by using the 
Immobilon Western Chemiluminescent HRP Substrate (Millipore Inc., USA; cat# WBKLSO100) 
according to the manufacturer’s protocol.  
Immunohistochemical (IHC) staining 
Excised tissues were fixed in 4% paraformaldehyde for 72 h, then were treated in 75% ethanol 
for 24 hrs, after which paraffin embedding was performed by automated instrumentation 
(University of Utah Histology Core). Embedded tissues were sectioned in 4 μm sections on a 
Leica microtome and mounted on glass slides. Sections were then deparaffinized and 
rehydrated (2 washes in xylene, 2 washes in 100% ethanol, 2 washes in 95% ethanol, 1 wash in 
water). Endogenous peroxidases were quenched by treating in 3% H2O2 in methanol for 10 min 
followed by 2 washes in 1x wash buffer (TA-999-TT Fisher Scientific). Sections were treated 
with Proteinase K for 10 min (Dako cat#S3020) then washed 2 times. Sections were then 
treated with Cyto-Q Background Buster (Innovex Biosciences) then washed 2 times. Primary 
rabbit anti-ASO antibody (Ionis Pharmaceuticals) diluted 1:40,000 in antibody diluent (2% BSA, 
5% normal donkey serum, in 1x Wash Buffer) was then incubated in on sections overnight at 
4°C. Sections were then washed 3 times and incubated in secondary donkey anti-rabbit-HRP 
antibody (Jackson ImmunoResearch) 1:200 in antibody diluent for 30 min at room temperature, 
followed by 3 washes in wash buffer.  Antibody detection was accomplished using DAB 
Chromagen (DAKO) followed by 2 washes in wash buffer. Sections were counterstainined using 
hematoxylin (Fisher), washed 2 times in water, dipped in an acid-ethanol decolorizing solution 
(500 μl HCI to 200 ml of 70% ethanol), and washed in water. Sections were then dehydrated (2 
washes in 95% ethanol, 2 washes in 100% ethanol, 2 washes in xylene) and mounded using 
permamount (Fisher). Peroxidase staining was imaged on an EVOS FL Microscope using 2x, 
10x, and 40x objectives. 
Antibodies  
The following antibodies were used for western blotting: ATXN2 mAb (1: 4000) (BD Biosciences 
Inc., 611378), 5TF1-1C2 mAb (1:3000) (Millipore Inc., MAB1574), RGS8 rabbit polyclonal Ab 
(1:5000) (Novus Biologicals, NBP2-20153), PCP-2 antibody (F-3) (1: 3000) (Santa Cruz Inc., sc-
137064), β-Actin mAb HRP conjugated (1:10,000) (Sigma Inc., A3854). The secondary 
antibodies were goat anti-mouse IgG-HRP antibody (1:5000) (Sigma Inc., A2304) and goat anti-
rabbit IgG-HRP antibody (1:5000) (Vector laboratories, PI-1000). Anti-ASO antibody (Ionis 
Pharmaceuticals) and appropriate secondary antibody used for IHC are described in the 
previous paragraph. 
Quantitative PCR 
Total RNA was extracted from cerebellar tissues, spinal cord tissues or SCA2-CAG35 patient 
fibroblasts using the RNeasyMini Kit (Qiagen Inc., USA) according to the manufacturer’s 
protocol. DNAse I treated RNAs were used to synthesize cDNAs using the ProtoScript cDNA 
First Strand cDNA Synthesis Kit (New England Biolabs Inc., USA). Primers for RT-PCR were 
designed to prevent amplification from genomic DNA (annealing sites in different exons or 
across intron-exon boundaries). PCR primers sequences are provided in Supplementary Table 
2. Quantitative RT-PCR was performed in Bio-Rad CFX96 (Bio-Rad Inc., USA) with the Power 
SYBR Green PCRMasterMix (Applied Biosystems Inc, USA). PCR reaction mixtures contained 
SYBR Green PCRMasterMix and 0.5 pmol primers and PCR amplification was carried out for 45 
cycles: denaturation at 95 °C for 10 sec, annealing at 60 °C for 10 sec and extension at 72 °C 
for 40 sec. The threshold cycle for each sample was chosen from the linear range and 
converted to a starting quantity by interpolation from a standard curve run on the same plate for 
each set of primers. Gene expression levels were normalized to the GAPDH or Actin mRNA 
levels.  
RNA sequencing 
Pcp2-ATXN2-Q127 or BAC-Q72 mice age 8 wks were treated with 210 μg ASO7 or normal 
saline. Following the final rotarod tests done at ages 21 and 18, respectively, cerebella from a 
selection of animals were then removed and total RNA prepared. Total RNA was isolated using 
miRNeasy Mini Kit (Qiagen Inc., USA). RNA integrity numbers >8 were verified using 
the Bioanalyzer 2100 Pico Chip (Agilent). Libraries were then prepared using the Illumina 
TrueSeq Stranded Total RNA Sample Prep with Ribo-Zero rRNA Removal Kit for mouse. 
Single-end 50-bp reads were generated on a Hiseq 2000 sequencing machine at the University 
of Utah Microarray and Genomic Analysis Shared Resource using Illumina Version 4 flow 
cells. Reads were then aligned to the mouse reference genome (mm10) by Novoalign. Quality 
of RNA sequencing was extremely high with an average of 28 million reads and 98 percent of 
the reads were aligned to the reference mouse genome. After read 
alignment, differentially expressed genes were identified using the DRDS application (version 
1.3.0) in the USeq software package. All p-values and AdjPs in the USeq output have been 
Phred transformed. Relationships between AdjP and p-values are as follows: AdjP>30, p<0.001; 
AdjP>20, p<0.01; AdjP>13, p<0.5. 
Rotarod Testing 
Cohorts of mice were bred from randomly selected breeding animals. Cohorts were selected 
randomly to have a balanced number of males and females. Rotarod groups were controlled for 
baseline rotarod performance as well as weight (treatment groups within any experiment had 
the same average rotarod latency to fall and weight before treatments). Rotarod testing was 
performed on the Rotamex-5 instrument (Columbus Instruments, Columbus OH). When 
performing tests, animals were taken to a separate testing room and habituated there for at 
least an hour before testing. Animals were tested in the same order, and beginning at the same 
time each day (1 p.m.). Mice in different treatment groups were housed together and the 
technician was blinded to treatment status. All rotarod testing in this study was performed by the 
same technician. Rotarod values per each week of testing were collected over five days. On day 
1 mice were handled for 2 minutes per mouse. On day 2 mice were introduced to the rotarod 
using the following paradigm: 4 RPM for 2 min, then increasing by 1 RPM per every 15 s to 10 
RPM for 60 s.  Tests on days 3-5 on the accelerating rotarod were identical with three tests per 
day as follows:  Mice were placed on the rod which from 0 RPM accelerated 1 RPM every 9 s 
until mice fell from the rod. Most mice fell before 40 RPM (6 min); all mice fell before 50 RPM 
(7.5 min).  Values of latency to fall in seconds were recorded. The rotarod was cleaned between 
individual tests. No animals were disqualified from testing once testing had begun, either during 
training or testing phases. 
Electrophysiology 
The preparation of parasagittal cerebellar slices closely followed our previously published 
description of the process5. Cerebella from BAC-Q72, ATXN2-Q127 and their age-matched WT 
littermates were removed and quickly immersed in 4 °C extracellular solution bubbled with 95% 
O2 and 5% CO2 (119 mM NaCl, 26 mM NaHCO3, 11 mM glucose, 2.5 mM KCl, 2.5 mM CaCl2, 
1.3 MgCl2 and 1 mM NaH2PO4, pH 7.4 when gassed with 5% CO2 / 95% O2). Parasagittal 
cerebellar slices (285 μm) were sectioned using a vibratome (Leica VT1000). Extracellular 
recordings were acquired in voltage-clamp mode at near physiological temperature (34.5 ± 1°C) 
using a dual channel heater controller (Model TC-344B, Warner Instruments) and constantly 
perfused with carbogen-bubbled extracellular solution at a rate of 3 ml per min. Cells were 
visualized on an upright microscope (Leica) with a 40x water-immersion lens.  Borosilicate glass 
pipettes with resistances between with 1 to 3 MΩ were filled with extracellular solution and used 
for recording action potential-associated capacitative current transients. The pipette potential 
was held at 0 mV and placed close to the Purkinje neuron axon hillock (soma/axon). Data were 
acquired at 20 kHz using a Multiclamp 700b amplifier, Digidata 1440 with pClamp10 (Molecular 
Devices) and filtered at 4 kHz. Each Purkinje neuron recording spanned a duration of 2 minutes 
and a total of 40 to >100 cells were measured from each mouse. A total of 1 to 4 mice per 
genotype were used and the experimenter was blinded to the mouse genotype. Experiments 
were analyzed using both Clampfit and Igor Program and further analyzed using Microsoft 
Excel. Figures were made using Igor. Results are presented as mean ±SEM. 
Statistical Analysis 
Statistical differences between selected groups evaluated by qPCR were determined by two-
tailed Student’s t-tests. Electrophysiological data were also evaluated using analysis of variance 
(ANOVA) tests followed by post-hoc tests of significance (Tukey’s multiple comparison test). 
Statistical comparisons of rotarod data were determined using the method of generalized 
estimating equations (GEE) with the independent correlation option using Stata 12 (procedures 
xtset followed by xtgee). The independent correlation option was employed because in the three 
day rotarod paradigm, regressions for wildtype mice frequently have more positive correlation 
coefficients than SCA2 mice. Regression analyses were performed using GraphPad Prism. 
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Supplementary Discussion 
Study Rigor 
a) Assurances of unbiased phenotype testing. 
Consensus criteria1 for the conduct of preclinical trials were closely followed to maintain the 
highest level of rigor. Mouse groups included a balance of males and females.  Upon weaning 
of mice we minimize litter effects by distributing pups in a manner such that littermates are 
never housed together. All mouse treatment trials were blinded to the tester. Randomized 
mouse groups for rotarod tests were arranged by a one technician and rotarod testing 
performed by a 2nd technician not aware of group assignment of mouse genotype. Group 
assignments were not identifiable by the technician performing phenotype evaluations. For 
rotarod testing, rotarod groups were controlled for baseline rotarod performance as well as 
weight. When mice were transported to the neurophysiology laboratory they were encoded such 
that ASO treatments were blinded to the investigator performing electrophysiology testing. We 
also blinded the technician performing qPCR analyses using mice post phenotype testing. 
These measures ensured that all determinations of the effects of ASO treatments on SCA2 
mice were made in an unbiased manner.  
b) Employment of multiple phenotype testing with replication. 
In our past efforts to characterize the motor phenotypes of SCA2 mice we have found the 
rotarod to be the most reliable test2,3. Rotarod tests have provided robust data with tighter 
standard deviations than observed in our efforts to characterize SCA2 mice using the beamwalk 
or DigiGait testing paradigms. We have not observed robust footprint data nor do we observe a 
consistent clasping phenotype for SCA2 mice. The rotarod paradigm also has the advantage 
that it is completely operator independent. We supplemented the behavioral phenotype with 
analyses of two additional phenotypes, one based on steady-state RNA and protein levels, and 
a second one based on neurophysiology in the acute slice. All of these were tested in two 
independent mouse models with independent replications. Restoration of normal or near normal 
Purkinje cell firing is of particular relevance as reduced PC firing is in  close temporal 
relationship with abnormal motor behavior and like the latter declines with progression of 
disease.  
 
Effect of mouse weight on rotarod test results 
We tested the weights of all mice before ASO treatments and at the time of all rotarod tests. We 
observed no evidence that mouse weight impaired the rotarod result (Extended Data Fig. 4). For 
the BAC mice weight is an issue that merits further discussion because of previous findings on 
BAC HD mice. In one study of BAC HD mice, the increased body weight of BAC HD mice 
impaired rotarod performance confounding the result4. However unlike BAC HD mice, ATXN2-
BAC-Q72 mice were lighter but performed worse than their WT littermates. At 10 weeks after 
ASO7 treatment, motor performance of BAC-Q72 mice had improved to a level not statistically 
different than the control groups (Fig. 1b). Therefore, body weight was not a confounding factor. 
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